Treatment of chronic type B hepatitis in Southeast Asia.
In Southeast Asia, 15 to 20 percent of the population are hepatitis B surface antigen carriers. The majority of these carriers have chronic hepatitis and would progress to cirrhosis or hepatocellular carcinoma at an annual incidence of 2 percent and 1 percent, respectively. Previous studies from Southeast Asia suggested that immunosuppressive therapy could be harmful, or at best of no value, and antiviral treatment with vidarabine, picibanil, or even interferon was also unsatisfactory. Currently, a randomized controlled trial of human lymphoblastoid interferon, with or without prednisolone pretreatment, versus placebo in patients with hepatitis B core antigen in the liver and hepatitis B e antigen in the serum is being conducted. Forty-five patients (29 receiving interferon, 16 receiving placebo) have been entered in the trial for at least two months. Actuarial analysis shows that the response to interferon therapy was better than that to placebo. Although flu-like symptoms, hair loss, and body weight loss were seen, no side effect requiring specific treatment has been encountered. These preliminary results suggest that human lymphoblastoid interferon is effective and safe in Oriental patients.
D001210:Asia, Southeastern; D002986:Clinical Trials as Topic; D005260:Female; D006509:Hepatitis B / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D011239:Prednisolone / Q000627:therapeutic use; D011897:Random Allocation; D013624:Taiwan
D007370:Interferon Type I; D010919:Placebos; D011239:Prednisolone